Literature DB >> 3994582

Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits.

A L Willis, B Nagel, V Churchill, M A Whyte, D L Smith, I Mahmud, D L Puppione.   

Abstract

Dutch-belted rabbits fed a 2% cholesterol diet for 8 weeks developed atherosclerotic lesions that covered 37.2% +/- 3.5% of the aortic luminal surface. In samples of aortic arch, accumulation of cholesterol and triglyceride was also observed. Oral administration of nicardipine or nifedipine at dosages of 40 mg/kg twice daily for 8 weeks reduced plaque area by 49.2% and 58.7%, respectively. Nicardipine and nifedipine reduced cholesterol accumulation in the aortic arch by 74.5% and 69%, respectively. Triglyceride accumulation was totally abolished. Neither drug significantly altered cholesterol concentration of plasma low density lipoprotein or high density lipoprotein, although nicardipine produced a 42% reduction in cholesterol concentration of the d less than 1.006 g/ml fraction. The above results suggest potential therapeutic utility of nicardipine in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994582     DOI: 10.1161/01.atv.5.3.250

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  24 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.

Authors:  Y Ohta; N Higuchi; S Emura; T Takashima; K Oogushi; H Kato; K Ohmori; T Sunaga
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 4.  Influence of nifedipine on experimental arteriosclerosis.

Authors:  A M Knorr; S Kazda
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 6.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

7.  Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study.

Authors:  J A Dens; W J Desmet; P Coussement; I K De Scheerder; K Kostopoulos; P Kerdsinchai; C Supanantaroek; J H Piessens
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

8.  Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.

Authors:  Mohamad C N Sinno; Mouaz Al-Mallah
Journal:  Cardiol Res Pract       Date:  2010-07-01       Impact factor: 1.866

9.  Differential and interactive effects of calcium channel blockers and cholesterol content of the diet on jejunal uptake of lipids in rabbits.

Authors:  D A Hyson; A B Thomson; C T Kappagoda
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

10.  Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade.

Authors:  A Daugherty; D L Rateri; G Schonfeld; B E Sobel
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.